bioAffinity Technologies Set for Continued Expansion in 2025
Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues
The Company’s wholly owned subsidiary Precision Pathology Laboratory Services (PPLS) is on track to report upwards of
“The seamless integration of Precision Pathology into bioAffinity Technologies since the acquisition is going to result in a record revenue year for the laboratory, due in part to the broader market adoption of CyPath® Lung,” bioAffinity President and CEO Maria Zannes said. “We count many successes in 2024, including obtaining reimbursement for CyPath® Lung, expanding our sales team, obtaining access to the federal healthcare system, and streamlining operations. We have the capability and the experience to expand operations exponentially to meet the growing demand for CyPath® Lung as we move to the national stage in 2025.”
CyPath® Lung revenues are expected to continue growing in 2025 with expanded sales into strategic national markets and inclusion in the
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding expansion and record revenues in 2025, the expected 2024 revenues from PPLS, growing demand for CyPath® Lung as the Company moves to the national stage in 2025, and CyPath® Lung revenues being expected to continue growing in 2025 with expanded sales into strategic national markets and inclusion in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212813114/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.